Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
RESEARCH TOOLSreports
Holding YMAB?
Track your performance easily
YMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.01 - $20.90
Previous CloseN/A
Volume43.26K
Average Volume (3M)424.72K
Market Cap
$279.93M
Enterprise Value$519.80M
Total Cash (Recent Filing)$16.88M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Feb 20, 2025EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding44,789,078
10 Day Avg. Volume519,336
30 Day Avg. Volume424,721
Standard Deviation0.24
R-Squared0.02
Alpha0.00012
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.31
Price to Cash Flow (P/CF)-6.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.86
Enterprise Value/Revenue6.15
Enterprise Value/Gross Profit7.08
Enterprise Value/Ebitda-20.57
Forecast
1Y Price Target
$19.43Price Target Upside215.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Y-Mabs Therapeutics News
PremiumCompany Announcements
Y-mAbs Therapeutics Updates on Business and Clinical Trials
PremiumCompany Announcements
Y-mAbs Therapeutics Announces Strategic Business Realignment
PremiumStock Analysis & Ideas
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
Bulls Say, Bears Say
Bulls Say
Clinical ResultsInitial data from the GD2-SADA platform is encouraging, showing no dose-limiting toxicities or treatment-related adverse events in 21 patients, supporting the platform's potential.
Corporate StrategyY-mAbs optimizes its corporate structure by establishing two business units to accelerate clinical development and optimize the commercial potential of DANYELZA.
Research And DevelopmentThe combination of CD38-SADA with Lu-177-DOTA reported robust tumor reduction, indicating promising results for future clinical applications.
Bears Say
Earnings PerformanceY-mAbs recorded a 3Q24 net loss of $0.16 per share compared to our previously forecasted net loss of $0.09 per share.
Revenue GuidanceFY24 revenue guidance decreased to $87M - $95M from previously $95M - $100M.
Workforce ReductionThe company plans to reduce its workforce by approximately 13% as part of the realignment.
---
Ownership Overview
23.86% Insiders
7.72% Mutual Funds
<0.01% Other Institutional Investors
57.60% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $6.01 and its highest was $20.90 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Y-Mabs Therapeutics’s market cap is $279.93M.
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 20 days.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on Nov 08, 2024. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.002.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 44,789,078 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went down -0.45%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Among the largest hedge funds holding Y-Mabs Therapeutics’s share is EntryPoint Capital, LLC. It holds Y-Mabs Therapeutics’s shares valued at 224K.
---
Y-Mabs Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.43 (215.93% Upside)
$19.43 (215.93% Upside)
Blogger Sentiment
Bearish
YMAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.14%
12-Months-Change
Fundamentals
Return on Equity
-24.78%
Trailing 12-Months
Asset Growth
-6.18%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
---
YMAB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Y-mAbs demonstrated strategic growth through partnerships and clinical advancements, the company faced revenue declines and increased operating expenses. Despite progress in physician adoption and ex-U.S. market expansion, challenges in the U.S. market and overall financial performance were notable.Read More>---
YMAB Stock 12 Month Forecast
Average Price Target
$19.43
▲(215.93% Upside)
Technical Analysis
Best Analysts Covering YMAB
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+58.53%
reiterated a buy rating 9 months ago
Copying William Maughan's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +58.53% per trade.
---